Chronic pain is one of the most common and expensive health problems in the nation, affecting an estimated one in five U.S. adults and costing around $600 billion each year in medical expenses, lost ...

Scientists have shown the efficacy of a new non-opioid oral painkiller known as ADRIANA, the world's first selective α2B-adrenoceptor antagonist – a receptor subtype not previously targeted for ...

Activation of the body’s opioid system may be required for ketamine’s antidepressant effects, new research hinted. In a small study of adults with major depressive disorder, taking the opioid blocker ...

The Food and Drug Administration (FDA) is recommending banning a compound found in unregulated tablets, gummies and drink mixes sold online and at gas stations and convenience stores, the Trump ...

Naloxone (also known as Narcan, the commonly used drug to treat narcotic overdoses) has greater binding to opioid receptors in women's brains than in men's brains, according to new research published ...

One of the greatest revolutions in the field of pain medication was the isolation of morphine from the opium poppy in the 19th century. Morphine molecules act as painkillers by attaching themselves to ...

Duke University researchers have devised a promising, potent pain reliever — seemingly without the harmful side effects and addictive highs of opioids. While opioids interact with numerous cellular ...

A new experimental painkiller has shown promise in dulling or eliminating pain without the addictive qualities exhibited by today's most popular opioids. The drug also sidesteps common opioid side ...

C. Michael White does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

New research suggests that δ-receptor agonists regulate intestinal motility and relieve abdominal pain in a mouse model of irritable bowel syndrome, potentially offering a novel CNS-targeted treatment ...

Shane Darke does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...